1
|
Ng LH, Ling JKU, Hadinoto K. Formulation Strategies to Improve the Stability and Handling of Oral Solid Dosage Forms of Highly Hygroscopic Pharmaceuticals and Nutraceuticals. Pharmaceutics 2022; 14:pharmaceutics14102015. [PMID: 36297450 PMCID: PMC9611293 DOI: 10.3390/pharmaceutics14102015] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2022] [Revised: 09/19/2022] [Accepted: 09/20/2022] [Indexed: 11/23/2022] Open
Abstract
Highly hygroscopic pharmaceutical and nutraceutical solids are prone to significant changes in their physicochemical properties due to chemical degradation and/or solid-state transition, resulting in adverse effects on their therapeutic performances and shelf life. Moisture absorption also leads to excessive wetting of the solids, causing their difficult handling during manufacturing. In this review, four formulation strategies that have been employed to tackle hygroscopicity issues in oral solid dosage forms of pharmaceuticals/nutraceuticals were discussed. The four strategies are (1) film coating, (2) encapsulation by spray drying or coacervation, (3) co-processing with excipients, and (4) crystal engineering by co-crystallization. Film coating and encapsulation work by acting as barriers between the hygroscopic active ingredients in the core and the environment, whereas co-processing with excipients works mainly by adding excipients that deflect moisture away from the active ingredients. Co-crystallization works by altering the crystal packing arrangements by introducing stabilizing co-formers. For hygroscopic pharmaceuticals, coating and co-crystallization are the most commonly employed strategies, whereas coating and encapsulation are popular for hygroscopic nutraceuticals (e.g., medicinal herbs, protein hydrolysates). Encapsulation is rarely applied on hygroscopic pharmaceuticals, just as co-crystallization is rarely used for hygroscopic nutraceuticals. Therefore, there is potential for improved hygroscopicity reduction by exploring beyond the traditionally used strategy.
Collapse
|
2
|
Veronica N, Heng PWS, Liew CV. Ensuring Product Stability – Choosing the Right Excipients. J Pharm Sci 2022; 111:2158-2171. [DOI: 10.1016/j.xphs.2022.05.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/28/2022] [Revised: 05/02/2022] [Accepted: 05/02/2022] [Indexed: 10/18/2022]
|
3
|
Ougi K, Okada K, Leong KH, Hayashi Y, Kumada S, Onuki Y. Effect of the molecular mobility of water adsorbed by disintegrants on storage-induced hydrolytic degradation of acetylsalicylic acid incorporated into tablets under humid conditions. Eur J Pharm Sci 2020; 154:105502. [DOI: 10.1016/j.ejps.2020.105502] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2020] [Revised: 07/10/2020] [Accepted: 07/30/2020] [Indexed: 12/24/2022]
|
4
|
Inoue Y, Iohara D, Sekiya N, Yamamoto M, Ishida H, Sakiyama Y, Hirayama F, Arima H, Uekama K. Ternary inclusion complex formation and stabilization of limaprost, a prostaglandin E1 derivative, in the presence of α- and β-cyclodextrins in the solid state. Int J Pharm 2016; 509:338-347. [PMID: 27286633 DOI: 10.1016/j.ijpharm.2016.06.018] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2016] [Revised: 05/26/2016] [Accepted: 06/06/2016] [Indexed: 11/29/2022]
Abstract
Limaprost/α-cyclodextrin (CD)/β-CD ternary inclusion complex was prepared by freeze-drying a solution containing all three components. Under humid conditions, limaprost was more stable in the ternary α-/β-CD inclusion complex than in the binary α- or β-CD complex. Specifically, during storage at 30°C/75% relative humidity (R.H.) for 4 weeks, about 19% of limaprost degraded into 17S,20-dimethyl-trans-Δ(2)-prostaglandin A1 (referred as 11-deoxy-Δ(10)) in the β-CD complex, 8.1% degraded in the α-CD complex, and only 2.2% degraded in the α-/β-CD complex. The mechanism of limaprost stabilization in the presence of both CDs was investigated by Raman and solid-state NMR spectroscopy and powder X-ray diffractometry. The fast degradation of limaprost to 11-deoxy-Δ(10) in the β-CD complex was due to the rapid crystallization of β-CD from the complex, liberating the free amorphous drug, which is susceptible to degradation. The dissociation and crystallization of β-CD from the inclusion complex were suppressed by freeze-drying limaprost in the presence of both α- and β-CDs. In addition, the interaction between limaprost and the two CDs was reinforced by inclusion of different moieties of limaprost: α-CD predominantly included the alkyl ω-chain, whereas β-CD included the five-membered ring. Thus, a stable ternary inclusion complex was formed that included limaprost, maintaining the amorphous state of the complex and dramatically stabilizing the drug under humid conditions.
Collapse
Affiliation(s)
- Yasuo Inoue
- CMC Regulatory and Analytical R&D, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan.
| | - Daisuke Iohara
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Noboru Sekiya
- Pharmaceutical Development Laboratories, Ono Pharmaceutical Co., Ltd., 3-1-1 Sakurai, Shimamoto-cho, Mishima-gun, Osaka 618-8585, Japan
| | - Masanobu Yamamoto
- CMC Strategy Development, Ono Pharmaceutical Co., Ltd., 8-2, Kyutaromachi 1-chome, Chuo-ku, Osaka 541-8564, Japan
| | - Hiroyuki Ishida
- Toray Research Center, Inc., 3-7 Sonoyama 3, Otsu, Shiga 520-8567, Japan
| | - Yoko Sakiyama
- Toray Research Center, Inc., 3-7 Sonoyama 3, Otsu, Shiga 520-8567, Japan
| | - Fumitoshi Hirayama
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| | - Hidetoshi Arima
- Graduate School of Pharmaceutical Sciences, Kumamoto University, 5-1 Oe-honmachi, Chuo-ku, Kumamoto 862-0973, Japan
| | - Kaneto Uekama
- Faculty of Pharmaceutical Sciences, Sojo University, 4-22-1 Ikeda, Nishi-ku, Kumamoto 860-0082, Japan
| |
Collapse
|
5
|
Inoue Y, Sekiya N, Yamamoto M, Iohara D, Hirayama F, Uekama K. Formation of the Ternary Inclusion Complex of Limaprost with α- and β-Cyclodextrins in Aqueous Solution. Chem Pharm Bull (Tokyo) 2015; 63:318-25. [DOI: 10.1248/cpb.c14-00733] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Yasuo Inoue
- CMC Regulatory and Analytical R&D, Ono Pharmaceutical Co., Ltd
| | | | | | | | | | | |
Collapse
|
6
|
Higashi K, Tozuka Y, Moribe K, Yamamoto K. Salicylic Acid/γ-Cydodextrin 2:1 and 4:1 Complex Formation by Sealed-Heating Method. J Pharm Sci 2010; 99:4192-200. [DOI: 10.1002/jps.22133] [Citation(s) in RCA: 34] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
|
7
|
Higashi K, Ideura S, Waraya H, Limwikrant W, Moribe K, Yamamoto K. Simultaneous Dissolution of Naproxen and Flurbiprofen from a Novel Ternary .GAMMA.-Cyclodextrin Complex. Chem Pharm Bull (Tokyo) 2010; 58:769-72. [DOI: 10.1248/cpb.58.769] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
| | - Saori Ideura
- Graduate School of Pharmaceutical Sciences, Chiba University
| | - Haruka Waraya
- Graduate School of Pharmaceutical Sciences, Chiba University
| | | | - Kunikazu Moribe
- Graduate School of Pharmaceutical Sciences, Chiba University
| | - Keiji Yamamoto
- Graduate School of Pharmaceutical Sciences, Chiba University
| |
Collapse
|
8
|
Sekiya N, Nishiwaki A, Nishiura A, Yamamoto M, Takeda K, Iohara D, Hirayama F, Arima H, Uekama K. Improved Stability of OPALMON Tablets under Humid Conditions IV: Effect of Polysaccharides and Disintegrants on the Stability and Dissolution Property of OPALMON Tablets. Chem Pharm Bull (Tokyo) 2008; 56:7-11. [DOI: 10.1248/cpb.56.7] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Affiliation(s)
- Noboru Sekiya
- Pharmaceutical Development Laboratories, Ono Pharmaceutical Co., Ltd
| | - Atsushi Nishiwaki
- Pharmaceutical Development Laboratories, Ono Pharmaceutical Co., Ltd
| | - Akio Nishiura
- Pharmaceutical Development Laboratories, Ono Pharmaceutical Co., Ltd
| | - Masanobu Yamamoto
- Pharmaceutical Development Laboratories, Ono Pharmaceutical Co., Ltd
| | - Kazuhisa Takeda
- Pharmaceutical Development Laboratories, Ono Pharmaceutical Co., Ltd
| | | | | | - Hidetoshi Arima
- Graduate School of Pharmaceutical Sciences, Kumamoto University
| | | |
Collapse
|